tradingkey.logo
tradingkey.logo
Search

Novo Nordisk Says Wegovy Pill Shows Greater Weight Loss Vs Orforglipron In New Indirect Comparison

ReutersApr 2, 2026 12:27 PM

- Novo Nordisk A/S NOVOb.CO:

  • NOVO NORDISK: WEGOVY PILL 25 MG SHOWED GREATER MEAN WEIGHT LOSS VERSUS. ORFORGLIPRON 36 MG IN POPULATION-ADJUSTED INDIRECT TREATMENT COMPARISON

  • NOVO NORDISK: POPULATION-ADJUSTED INDIRECT TREATMENT COMPARISON USES DATA FROM OASIS 4 & ATTAIN-1 CLINICAL TRIALS

  • NOVO NORDISK: IN SEPARATE PATIENT PREFERENCE STUDY, 84% FAVORED WEGOVY PILL 25MG-LIKE TREATMENT PROFILE VERSUS. ORFORGLIPRON-LIKE PROFILE

  • NOVO NORDISK: ORFORGLIPRON 36MG TREATMENT HAD ABOUT 14 TIMES HIGHER DISCONTINUATION ODDS DUE TO GASTROINTESTINAL ADVERSE EVENTS VERSUS WEGOVY PILL 25MG

Further company coverage: [NOVOb.CO]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI